Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...
Based on the pivotal role of dMMR/MSI-H status in treatment selection for CRC, the National Comprehensive Cancer Network® (NCCN®) guidelines for colon and rectal cancer recommend universal MMR or MSI ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results